The 7th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference (Hereinafter referred to as MIM) will be held on April 15-20, 2018 in Dakar, Senegal, Africa. As the highest-level academic conference in the global malaria field, MIM has successfully held six sessions so far.
Since its establishment in 1997, this is the second time that the conference has returned to Senegal in 20 years. It is expected that the one-week conference will attract nearly 3,000 attendees from malaria related academic institutions, government and non-governmental organizations, and representatives of pharmaceutical companies. World renowned malaria scientists and front-line researchers in Africa will gather in Dakar together to discuss the current status and future of humans ‘fight against malaria, making MIM an ideal information exchange platform in malaria research hand “production-learning-research” cooperation between different organization.
As one of the world’s leading suppliers of antimalarial drugs, Fosun Pharma actively participates in this world class malaria academic event. On the morning of April 17, Fosun Pharma will join hands with 5 well acknowledged malaria experts in the MIM conference center to present a symposium themed “At the Crossroad of Antimalarial Drug Resistance: Challenges and Solutions”. The 2 hours’ symposium will focuses on the concern about the resistance of antimalarial drug resistance and propose some l alternative solutions.
During the six-day MIM conference week, visitors are also welcomed to visit the Fosun Pharma booth in the exhibition hall to learn more information about the company, its antimalarial drugs, and the actions and determination of Fosun Pharma’s full participation in the global fight against malaria. A brand new package of Artesun® (Artesunate for injection) the company’s key product, will also be released during the MIM. By changing cooperate logo from GPSC to Fosun Pharma, the new package reflects Fosun Pharma's commitment of product quality to malaria patients.
Date: April 17, 2018
Theme：At the Crossroad of Antimalarial Drug Resistance: Challenges and Solutions
Location：Salle ovale/the ovale meeting room international conference centre abdou diouf Senegal
Time: April 15-20, 2018
Venue: Dakar International Conference Center, Senegal
Booth number: 129/130/137/138
Malaria, tuberculosis and AIDS are the world’s top 3 public health threats. Nearly half of the world’s population is at risk of malaria, and sub-Saharan Africa continues to carry a disproportionately high share of the global malaria burden. In 2016, there were roughly216 million malaria cases in the world with an estimated number of 445,000 malaria deaths. Malaria is an infectious disease caused by Plasmodium parasites spreading to humans through the bites of infected mosquitoes. Once infected, people usually develop non specifics symptoms such as fever, chills, and nausea or vomiting. If not treated promptly with effective antimalarial drugs, uncomplicated malaria will deteriorate into severe malaria and cause severe complications and even death.
The Multilateral Initiative on Malaria
The Multilateral Initiative on Malaria has been founded in 1997, its MIM Pan-African Malaria Conference is held every 3-5 years. It aims to strengthen the malaria epidemic in Africa by promoting scientific exchanges, cooperation and training among international agencies and companies, to enhance the country’s ability to fight malaria.Since its establishment, MIM has gradually formed a dynamic network system centering on malaria research and has made significant contributions to the global anti-malaria work through cooperation with African malaria research.
About Artesunate for injection（Artesun®）
Fosun Pharma's member company, Guilin Pharmaceutical, is a global leader in anti-malarial drug R&D and manufacturing. Its products cover malaria prevention, routine treatment, and rescue of critically ill patients. To help prevent more severe malaria patients worldwide from death threats, Fosun Pharma started the WHO PQ certification for Artesunate for injection（Artesun®）in 2005. Five years later, Artesun® officially became a member on November 5, 2010. The first WHO PQ certified medicine for severe malaria treatment.At present, the global sales of Artesun® has exceeded 100 million vials to help recovery more than 20 million critical malaria patients in worldwide, most of who are children under 5 years old.